The Short Answer
Zepbound and Mounjaro are the exact same medication — tirzepatide — manufactured by Eli Lilly, in the same doses, in the same injection pens. Neither is "better" because they are chemically identical. The only differences are the FDA-approved indication (weight loss vs diabetes) and how insurance companies categorize them. Which one you should get depends entirely on your diagnosis and your insurance plan.
Key Facts
- Both contain tirzepatide, a dual GIP/GLP-1 receptor agonist, at identical doses (2.5mg through 15mg)
- Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for weight loss and sleep apnea
- Mounjaro costs ~$1,069–$1,112/month retail; Zepbound costs ~$1,059–$1,112/month retail
- Zepbound has a $299/month cash-pay option through LillyDirect; Mounjaro does not
- Insurance is far more likely to cover Mounjaro for diabetes than Zepbound for weight loss
- Side effects, dosing schedule, and efficacy are identical because it's the same drug
Why the Same Drug Has Two Names
Pharmaceutical companies routinely sell the same medication under different brand names for different FDA-approved conditions. Eli Lilly ran two separate clinical trial programs — SURPASS for diabetes and SURMOUNT for weight loss — to earn separate approvals. This isn't unusual: semaglutide is sold as Ozempic (for diabetes) and Wegovy (for weight loss) by Novo Nordisk.
The practical consequence is that insurance companies treat them as completely different medications. A diabetes drug and a weight loss drug go through different formulary processes, different prior authorization requirements, and often different coverage decisions — even though the molecule sitting in the pen is identical.
The Complete Comparison
| Feature | Zepbound | Mounjaro |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA Approval | Weight management + sleep apnea | Type 2 diabetes |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg |
| How Taken | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Retail Price (no insurance) | ~$1,059–$1,112/mo | ~$1,069–$1,112/mo |
| Cash-Pay Program | $299/mo (LillyDirect) | No equivalent program |
| With Insurance + Savings Card | $25/mo (commercial) | $25/mo (commercial) |
| Medicare Coverage | Generally not covered for weight loss | ~$50/mo (some Part D plans) |
| Side Effects | Identical (nausea, diarrhea, constipation) | Identical |
| Weight Loss Data | ~20.9% average (SURMOUNT-1) | Same drug, same results |
Which One to Get: Three Scenarios
Scenario 1: You have type 2 diabetes
Get Mounjaro. It's FDA-approved for your condition, and insurance coverage is much more likely. Many commercial plans cover Mounjaro for diabetes, and Medicare Part D is increasingly covering it. The Lilly Savings Card can bring your copay down to $25/month on commercial insurance. You'll still lose weight — the drug is identical — but your insurance path is cleaner.
Scenario 2: You want weight loss without diabetes
Get Zepbound. It's the FDA-approved option for chronic weight management. Insurance coverage for weight loss drugs is growing but still inconsistent. If your plan doesn't cover it, LillyDirect offers it at $299/month as a cash-pay option — no insurance needed. This is the only manufacturer-direct cash program for tirzepatide.
Scenario 3: You have both diabetes and excess weight
Talk to your prescriber about Mounjaro first. It may offer the better insurance coverage pathway since diabetes has broader formulary inclusion than weight management. Either way, the drug treats both conditions simultaneously because the molecule is the same.
The Compounded Alternative
For patients who can't access brand-name tirzepatide at an affordable price, compounded tirzepatide is available through telehealth providers at $125–$399/month. Compounded versions contain the same active ingredient but are not FDA-approved finished products.
Important: compounded tirzepatide availability has tightened since the FDA declared tirzepatide no longer in shortage in late 2025. Fewer compounding pharmacies have the regulatory standing to produce it, and prices have risen. Compounded semaglutide remains more widely available as an alternative GLP-1 option.
Synergy Rx — Compounded Tirzepatide
All-inclusive pricing on compounded semaglutide and tirzepatide. Medication, consult, and shipping included.
Sesame Care — Brand-Name Tirzepatide Prescriptions
Prescribes FDA-approved brand-name medications including Zepbound and Mounjaro. No compounded alternatives.
Frequently Asked Questions
Is Zepbound stronger than Mounjaro?
No. They contain the same medication at the same doses. Your body cannot tell the difference between a shot of Zepbound and a shot of Mounjaro. The molecule is identical.
Can I switch between Zepbound and Mounjaro?
In terms of pharmacology, yes — it's the same drug. But switching brands may require a new prescription and new insurance authorization. Your doctor can determine the most practical approach based on your coverage situation.
Can I use Mounjaro for weight loss if I don't have diabetes?
Doctors can prescribe Mounjaro "off-label" for weight loss, but insurance companies are increasingly rejecting off-label claims for weight management. You would likely need to pay out of pocket. Zepbound is the FDA-approved path for weight loss without diabetes.
Is there a generic tirzepatide?
No. Both Zepbound and Mounjaro are patent-protected until at least 2036. Generic tirzepatide is not expected to be available in the United States for many years.
Which has fewer side effects?
Neither — they're the same drug. Common side effects for both include nausea, diarrhea, constipation, vomiting, and abdominal pain, especially during dose escalation. These typically improve as your body adjusts.
Don't ask "which is better?" — the medication is identical. The real question is: "Which label gives me the most affordable access given my diagnosis and insurance plan?" For diabetes, that's usually Mounjaro. For weight loss, it's Zepbound. For cash-pay without insurance, LillyDirect at $299/month (Zepbound) or compounded tirzepatide at $125–$399/month are the most practical paths.